

Project Title	Quebec Cancer Consortium for new therapeutic agents and biomarkers
Principal Investigator	Morag Park
Principal Institute	McGill University (Rosalind and Morris Goodman Cancer)
Summary	
<p>This project aims to create one of the most dynamic North American poles of research and innovation in oncology. Building on alliances established between six of the largest hospitals and research centers in oncology at McGill University and the University of Montreal, the Quebec Cancer Consortium (QCC) will be one of the most important poles of innovation in oncology in North America. Collectively, the QCC will harness the power of databases of more than 16,000 cancer patients each year. The consortium will leverage investments from the Terry Fox Research Institute and several pharmaceutical partners, and will integrate unique oncology platforms, advanced clinical trials, the Rossy Cancer Network, the FRQS-Cancer Network, Oncopole, and the Exactis Innovations and C3i National Centers of Excellence, to innovate in the implementation and sustainability of precision medicine for the treatment of cancer patients in the Quebec healthcare system. The consortium will develop new strategies to identify and overcome treatment resistance and improve adverse events associated with personalized medicine, including emerging immunotherapies applicable to multiple cancers with an urgent medical need.</p> <p>The QCC will standardize and harmonize best practices in oncology between hospitals and research centers, identify Quebec as a national and international leader, establish new commercial partnerships, improve diagnosis and stimulate the biotechnology sector in Quebec. The QCC will lead to major advances in the recruitment and training of the next generation of clinicians and researchers, making Quebec a leader in innovation and improved cancer care.</p>	